Sofgen Pharma S.A. (OTCPK: PROC.F)
Health Care · Pharmaceuticals · LU
$0.00
— today · -100.0% 1Y
Sofgen Pharma S.A. (OTCPK: PROC.F) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $697.44K and employs 5,500 people.
Over the last twelve months the share price has lost 100.0%, trading between 0.00 and 1.40.
Tweenvest scores Sofgen Pharma S.A. across four factors: quality 52/100, value 72/100, growth 9/100. Its strongest factor is value.
PROC.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $697.44K
- Revenue (TTM)
- $373.80M
- P/E
- —
- EPS
- -0.68
- Dividend yield
- —
- Beta (5Y)
- 56.74
- 52-week high
- $1.40
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.32B
- Employees
- 5,500
- Next earnings
- —
About Sofgen Pharma S.A.
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- ISIN
- LU2376511205
- Founded
- 1977
- Listed since
- Dec 9, 2019
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.